{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:07:09Z","timestamp":1788502029059,"version":"build-2803163510"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>The comparative impact of everolimus (EVR)-based regimens versus standard of care (mycophenolic acid+standard calcineurin inhibitor [MPA+sCNI]) on cardiovascular outcomes in de novo kidney transplant recipients (KTRs) is poorly understood. The incidence of major adverse cardiac events (MACEs) in KTRs receiving EVR+reduced CNI (rCNI) or MPA+sCNI from the TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen study was evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>The incidence of MACE was determined for all randomized patients receiving at least 1 dose of the study drug. Factors associated with MACEs were determined by logistic regression. Risk of MACE out to 3 y post-study was calculated using the Patient Outcome in Renal Transplantation equation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>MACE occurred in 81 of 1014 (8.0%; EVR+rCNI) versus 89 of 1012 (8.8%; MPA+sCNI) KTRs (risk ratio, 0.91 [95% confidence interval [CI], 0.68-1.21]). The incidence of circulatory death, myocardial infarction, revascularization, or angina was similar between the arms. Incidence of MACE was similar between EVR+rCNI and MPA+sCNI arms with a higher incidence in prespecified risk groups: older age, pretransplant diabetes (15.1% versus 15.9%), statin use (8.5% versus 10.8%), and low estimated glomerular filtration rate (Month 2 estimated glomerular filtration rate &lt;30 versus &gt;60\u2009mL\/min\/1.73 m<jats:sup>2<\/jats:sup>; odds ratio, 2.23 [95% CI, 1.02-4.86]; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.044), respectively. Predicted risk of MACE within 3 y of follow-up did not differ between the treatment arms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Cardiovascular morbidity and mortality were similar between de novo KTRs receiving EVR+rCNI and MPA+sCNI. EVR+rCNI is a viable alternative to the current standard of care in KTRs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004555","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T05:03:52Z","timestamp":1679634232000},"page":"1593-1604","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study"],"prefix":"10.1097","volume":"107","author":[{"given":"Claudia","family":"Sommerer","sequence":"first","affiliation":[{"name":"Department of Nephrology, Heidelberg University Hospital, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Legendre","sequence":"additional","affiliation":[{"name":"Department of Adult Kidney Transplantation, H\u00f4pital Necker, Universit\u00e9 de Paris, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Citterio","sequence":"additional","affiliation":[{"name":"Agostino Gemelli University Polyclinic Foundation, Catholic University of the Sacred Heart, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Watarai","sequence":"additional","affiliation":[{"name":"Department of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya\u2010City, Aichi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Oberbauer","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, University Clinic for Internal Medicine III, Medical University Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolina","family":"Basic-Jukic","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, Zagreb, Croatia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Han","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Gawai","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt Ltd, Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bernhardt","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Chadban","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney Local Health District, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.semnephrol.2018.02.008","article-title":"Cardiovascular disease after kidney transplant.","volume":"38","author":"Rao","year":"2018","journal-title":"Semin Nephrol"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1681\/ASN.2020050566","article-title":"Death after kidney transplantation: an analysis by era and time post-transplant.","volume":"31","author":"Ying","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0140-6736(11)61334-2","article-title":"Prevention of cardiovascular disease in adult recipients of kidney transplants.","volume":"378","author":"Jardine","year":"2011","journal-title":"Lancet"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/TP.0000000000003224","article-title":"Cardiac mortality in kidney transplant patients: a population-based cohort study 1988-2013 in Australia and New Zealand.","volume":"105","author":"Wyld","year":"2021","journal-title":"Transplantation"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.kint.2019.06.026","article-title":"Prediabetes is a risk factor for cardiovascular disease following renal transplantation.","volume":"96","author":"Porrini","year":"2019","journal-title":"Kidney Int"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40620-018-0549-4","article-title":"Cardiovascular risk in renal transplant recipients.","volume":"32","author":"Devine","year":"2019","journal-title":"J Nephrol"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/01.TP.0000061602.03327.E2","article-title":"Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation.","volume":"75","author":"Meier-Kriesche","year":"2003","journal-title":"Transplantation"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/j.1600-6143.2012.04101.x","article-title":"Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial.","volume":"12","author":"Weiner","year":"2012","journal-title":"Am J Transplant"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1034\/j.1600-6143.2002.20902.x","article-title":"Cardiovascular toxicities of immunosuppressive agents.","volume":"2","author":"Miller","year":"2002","journal-title":"Am J Transplant"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/TP.0b013e31826e592e","article-title":"Calcineurin inhibition and new-onset diabetes mellitus after transplantation.","volume":"95","author":"Chakkera","year":"2013","journal-title":"Transplantation"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ctr.12045","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.","volume":"27","author":"Shihab","year":"2013","journal-title":"Clin Transplant"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/ajt.14215","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus.","volume":"17","author":"Shihab","year":"2017","journal-title":"Am J Transplant"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/ajt.14090","article-title":"Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data.","volume":"17","author":"Qazi","year":"2017","journal-title":"Am J Transplant"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.","volume":"95","author":"Cibrik","year":"2013","journal-title":"Transplantation"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jacl.2019.01.011","article-title":"Management of dyslipidemia in adult solid organ transplant recipients.","volume":"13","author":"Warden","year":"2019","journal-title":"J Clin Lipidol"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.trre.2019.07.001","article-title":"Evidence-based practice: guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients.","volume":"33","author":"Pascual","year":"2019","journal-title":"Transplant Rev (Orlando)"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jchf.2013.07.002","article-title":"Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the everolimus versus mycophenolate mofetil randomized, multicenter trial.","volume":"1","author":"Kobashigawa","year":"2013","journal-title":"JACC Heart Fail"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"e004050","DOI":"10.1161\/CIRCHEARTFAILURE.117.004050","article-title":"Effect of everolimus initiation and calcineurin inhibitor elimination on cardiac allograft vasculopathy in de novo heart transplant recipients.","volume":"11","author":"Arora","year":"2018","journal-title":"Circ Heart Fail"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1097\/TP.0000000000001739","article-title":"Cardiovascular parameters to 2 years after kidney transplantation following early switch to everolimus without calcineurin inhibitor therapy: an analysis of the randomized ELEVATE study.","volume":"101","author":"Holdaas","year":"2017","journal-title":"Transplantation"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1097\/TP.0000000000001691","article-title":"mTOR inhibition and cardiovascular diseases: cardiac hypertrophy.","volume":"102","author":"Paoletti","year":"2018","journal-title":"Transplantation"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation.","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.","volume":"19","author":"Berger","year":"2019","journal-title":"Am J Transplant"},{"key":"R23-20250604","first-page":"13","article-title":"Proteinuria and its relation to cardiovascular disease.","volume":"7","author":"Currie","year":"2014","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1600-6143.2009.02949.x","article-title":"Predicting coronary heart disease after kidney transplantation: patient outcomes in renal transplantation (PORT) study.","volume":"10","author":"Israni","year":"2010","journal-title":"Am J Transplant"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1034\/j.1399-0012.2003.00063.x","article-title":"Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation.","volume":"17","author":"Asberg","year":"2003","journal-title":"Clin Transplant"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/qjmed\/hcx040","article-title":"Meta-analysis of statins in chronic kidney disease: who benefits?","volume":"110","author":"Messow","year":"2017","journal-title":"QJM"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1681\/ASN.2018111101","article-title":"Long-term outcomes after acute rejection in kidney transplant recipients: an ANZDATA analysis.","volume":"30","author":"Clayton","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/jdi.13397","article-title":"Trends in the effects of pre-transplant diabetes on mortality and cardiovascular events after kidney transplantation.","volume":"12","author":"Jeon","year":"2021","journal-title":"J Diabetes Investig"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1600-6143.2007.02101.x","article-title":"Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes.","volume":"8","author":"Cosio","year":"2008","journal-title":"Am J Transplant"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/ctr.12080","article-title":"Pre-existing diabetes significantly increases the risk of graft failure and mortality following renal transplantation.","volume":"27","author":"Taber","year":"2013","journal-title":"Clin Transplant"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S2213-8587(16)30317-5","article-title":"Long-term outcomes of kidney transplantation in people with type 2 diabetes: a population cohort study.","volume":"5","author":"Lim","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.transproceed.2012.11.013","article-title":"Kidney transplantation in type 2 diabetic patients: a matched survival analysis.","volume":"45","author":"Rocha","year":"2013","journal-title":"Transplant Proc"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.semnephrol.2022.04.006","article-title":"Sex-based differences in risk factors and complications of CKD.","volume":"42","author":"Wyld","year":"2022","journal-title":"Semin Nephrol"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1111\/ajt.14258","article-title":"Filtration markers, cardiovascular disease, mortality, and kidney outcomes in stable kidney transplant recipients: the FAVORIT trial.","volume":"17","author":"Foster","year":"2017","journal-title":"Am J Transplant"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1161\/01.CIR.0000130641.08705.45","article-title":"Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload.","volume":"109","author":"McMullen","year":"2004","journal-title":"Circulation"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000057979.36322.88","article-title":"Rapamycin attenuates load-induced cardiac hypertrophy in mice.","volume":"107","author":"Shioi","year":"2003","journal-title":"Circulation"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/01.hjh.0000239304.01496.83","article-title":"Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis.","volume":"24","author":"Gao","year":"2006","journal-title":"J Hypertens"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/j.jacc.2009.08.031","article-title":"Beneficial effects of mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction.","volume":"54","author":"Buss","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.111.040360","article-title":"Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation.","volume":"125","author":"Topilsky","year":"2012","journal-title":"Circulation"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/eurheartj\/ehn407","article-title":"Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients.","volume":"29","author":"Kushwaha","year":"2008","journal-title":"Eur Heart J"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/TP.0b013e318189049a","article-title":"Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft.","volume":"86","author":"Raichlin","year":"2008","journal-title":"Transplantation"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ajt.12181","article-title":"Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.","volume":"13","author":"Eisen","year":"2013","journal-title":"Am J Transplant"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1097\/HJH.0b013e32830ef940","article-title":"Switch of immunosuppression from cyclosporine a to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients.","volume":"26","author":"Seckinger","year":"2008","journal-title":"J Hypertens"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/j.1600-6143.2011.03697.x","article-title":"Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine.","volume":"11","author":"Joannides","year":"2011","journal-title":"Am J Transplant"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.ajkd.2008.04.018","article-title":"Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial.","volume":"52","author":"Paoletti","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/tri.12862","article-title":"Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.","volume":"29","author":"Cruzado","year":"2016","journal-title":"Transpl Int"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1111\/ajt.14948","article-title":"De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: a trial-based linkage study.","volume":"18","author":"Ying","year":"2018","journal-title":"Am J Transplant"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.kint.2016.11.008","article-title":"The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.","volume":"91","author":"Lim","year":"2017","journal-title":"Kidney Int"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:08:08Z","timestamp":1749060488000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004555","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,20]]}}}